Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Hamberg, Paul
REDOSE, NCT03927391: Effect of a Reduced Dose Enzalutamide in Frail (m)CRPC Patients on Cognitive Side Effects	Completed	4	57	Europe	Enzalutamide	Radboud University Medical Center	Prostatic Neoplasms, Castration-Resistant	01/24	01/24
MIND THE GAP, NCT05339672: Determining the Clinical Relevance of the Interaction Between Enzalutamide and the Opioid Morphine and the DOAC Edoxaban	Recruiting	N/A	26	Europe	Blood sampling - Pharmacokinetic assessment	Radboud University Medical Center, Astellas Pharma Inc	Drug-drug Interaction	08/24	08/24

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Hamberg, Paul
REDOSE, NCT03927391: Effect of a Reduced Dose Enzalutamide in Frail (m)CRPC Patients on Cognitive Side Effects	Completed	4	57	Europe	Enzalutamide	Radboud University Medical Center	Prostatic Neoplasms, Castration-Resistant	01/24	01/24
MIND THE GAP, NCT05339672: Determining the Clinical Relevance of the Interaction Between Enzalutamide and the Opioid Morphine and the DOAC Edoxaban	Recruiting	N/A	26	Europe	Blood sampling - Pharmacokinetic assessment	Radboud University Medical Center, Astellas Pharma Inc	Drug-drug Interaction	08/24	08/24